Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rapport Therapeutics

Request full access

Developing recision medicines to match the complexity of the human brain

Boston, United StatesFounded 2022Biotech & Life Sciences

About Rapport Therapeutics

Rapport Therapeutics is a scientific partnership startup focused on the development of precision neuromedicines. The company is led by Steve, a seasoned professional with over 40 years of R&D leadership experience. He has co-founded and led multiple companies in the biotechnology and pharmaceutical industry, including Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics.

Rapport operates in the healthcare and pharmaceutical market, specifically targeting neurological disorders. The company's primary clients are patients suffering from drug-resistant epilepsies and mood disorders. Rapport's business model revolves around the discovery and development of novel drugs that act only on disease-relevant areas in the brain, thereby reducing symptoms and side effects of treatment regimens.

Rapport's discovery platform is designed to identify drugs with selectivity to enhance patient benefit. This is achieved by embedding region-specific RAPs (Receptor Associated Proteins) into their drug discovery and development processes. RAPs function in discrete and specific cell types or brain regions, and by targeting these areas, Rapport aims to create more effective treatments for neurological disorders.

The company generates revenue through the development and sale of these precision neuromedicines. Additionally, they may also earn income from conducting clinical trials and providing related services.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2024
Employees
102
Open positions
12
Dealroom signal
57.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Neurology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Sep 2025 $250M — Undisclosed ↗
IPOOther financing Jun 2024 $154M $601M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Rapport Therapeutics website traffic

Latest recorded traffic for Rapport Therapeutics is 7.8K monthly website visits, up 25.8% over the last three months. Rapport Therapeutics's team grew 15.9% over the past year.

Latest monthly visits7.8K 3-month web change+25.8% 1-year team growth+15.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Rapport Therapeutics in the Boston ecosystem

Live from Dealroom

The Rapport Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Rapport Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.